Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01383538 · ClinicalTrials.gov registry record · Phase 1
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Andrew Ko.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT01383538: Completed Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Andrew Ko.
NCT01383538 is a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms that has completed, run by Andrew Ko. The registered enrollment target is 15 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01383538, a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, has completed, sponsored by Andrew Ko.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
Conditions Studied
Interventions
- DRUG FOLFIRINOX, IPI-926
Study Locations (3)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Wisconsin
- University of Wisconsin Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-08-23 |
| Est. Completion | 2015-05-26 |
| Phase | Phase 1 |
What the finished NCT01383538 record still lists
NCT01383538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which FOLFIRINOX, IPI-926 is the first listed.
NCT01383538 reports a single indexed study location in California, Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01383538 about?
NCT01383538 is a clinical study titled "FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma". The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
What is the current status of trial NCT01383538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2011-08-23. Estimated completion is 2015-05-26.
What conditions does trial NCT01383538 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Neoplasms, Adenocarcinoma.
What interventions are being tested in trial NCT01383538?
The interventions under investigation include: FOLFIRINOX, IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01383538?
This trial is sponsored by Andrew Ko, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01383538 being conducted?
This trial has 3 study locations across California, Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01383538's enrollment target sits among peer trials
15 247th of 278 higher than 27 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI